阿沙替利单抗用于至少两种既往全身治疗失败的慢性移植物抗宿主病:I/II期研究结果
这项I/II期开放标签研究评估阿沙替利单抗在≥2线全身治疗失败的活跃性慢性移植物抗宿主病(cGVHD)患者中的安全性、耐受性和疗效。40例患者入组,I期确定3 mg/kg每4周一次为最佳生物剂量,II期第7周期第1天总缓解率(ORR)达50%并达到主要终点,前6周期ORR为82%。
要点
- I期确定阿沙替利单抗最佳生物剂量为3 mg/kg每4周一次。
- II期第7周期第1天ORR为50%,达到主要疗效终点。
- 前6周期ORR为82%,所有受累器官均见缓解。
核心结论
- 靶向促纤维化巨噬细胞的阿沙替利单抗是治疗难治性cGVHD的一种治疗上有前景的新策略,安全性特征良好。
研究设计与样本
- I/II期开放标签研究(ClinicalTrials.gov标识符:NCT03604692),评估阿沙替利单抗在≥6岁、≥2线既往全身治疗后活跃性cGVHD患者中的安全性、耐受性和疗效。
- I期主要目标为确定最佳生物剂量和II期推荐剂量,II期主要目标为评估治疗第7周期开始时的总缓解率(ORR,完全缓解和部分缓解)。
- 共40例入组患者(I期17例;II期23例)接受至少一剂阿沙替利单抗。
主要发现
- I期中,3 mg/kg每4周一次给药满足最佳生物剂量定义。
- 3 mg/kg每2周一次给药时发生2例剂量限制性毒性。
- 30例患者观察到至少1例治疗相关不良事件(TRAE),8例发生≥3级TRAE,多数为已知的CSF-1R抑制的靶向效应。
- 未发生巨细胞病毒再激活。
- II期队列第7周期第1天ORR为50%,达到主要疗效终点;前6周期ORR为82%(支持监管批准的终点)。
关键数值与推荐
- I期最佳生物剂量:3 mg/kg每4周一次。
- II期主要疗效终点:第7周期第1天ORR为50%。
- 前6周期ORR为82%。
- 58%的患者报告Lee症状量表cGVHD相关症状显著改善。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Chronic graft-versus-host disease (cGVHD) remains the major cause of late morbidity after allogeneic hematopoietic cell transplantation. Colony-stimulating factor 1 receptor (CSF-1R)-dependent macrophages promote cGVHD fibrosis, and their elimination in preclinical studies ameliorated cGVHD. Axatilimab is a humanized monoclonal antibody that inhibits CSF-1R signaling and restrains macrophage development. PATIENTS AND METHODS: This phase I (phI)/phase II (phII) open-label study (ClinicalTrials.gov identifier: NCT03604692) evaluated safety, tolerability, and efficacy of axatilimab in patients age ≥ 6 years with active cGVHD after ≥ 2 prior systemic therapy lines. Primary objectives in phI were to identify the optimal biologic and recommended phII dose and in phII to evaluate the overall (complete and partial) response rate (ORR) at the start of treatment cycle 7. RESULTS: Forty enrolled patients (17 phI; 23 phII) received at least one axatilimab dose. In phI, a dose of 3 mg/kg given once every 4 weeks met the optimal biologic dose definition. Two dose-limiting toxicities occurred at the 3 mg/kg dose given once every 2 weeks. At least one treatment-related adverse event (TRAE) was observed in 30 patients with grade ≥ 3 TRAEs in eight patients, the majority known on-target effects of CSF-1R inhibition. No cytomegalovirus reactivations occurred. With the 50% ORR at cycle 7 day 1, the phII cohort met the primary efficacy end point. Furthermore, the ORR in the first six cycles, an end point supporting regulatory approvals, was 82%. Responses were seen in all affected organs regardless of prior therapy. Fifty-eight percent of patients reported significant improvement in cGVHD-related symptoms using the Lee Symptom Scale. On-target activity of axatilimab was suggested by the decrease in skin CSF-1R-expressing macrophages. CONCLUSION: Targeting profibrotic macrophages with axatilimab is a therapeutically promising novel strategy with a favorable safety profile for refractory cGVHD.
引用
- Kitko CL, Arora M, DeFilipp Z, et al. Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study. J Clin Oncol. 2022. PMID: 36459673. doi:10.1200/JCO.22.00958
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。